Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Other EventsItem 8.01 Other Events.
On August 14, 2017, Spotlight Innovation Inc. (the “Company”) entered into a Sponsored Research Agreement (the “Agreement”) with The Trustees of Indiana University (“IU”) to support research directed by IU professor Dr. Elliot Androphy aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy. Dr. Androphy is a member of the Company’s scientific advisory board.
The Company will provide to IU an aggregate of $75,000 in funding support for the research project. The Company shall sponsor IU’s research project for a period of one (1) year, unless sooner terminated by either party upon forty-five days advance written notice to the terms of the Agreement.
About Spotlight Innovation Inc. (OTCMKTS:STLT)
Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.